Search QAs

1) As you specified, the insurance intermediary requesting to do cross-border insurance intermediation in FOS in a host-State, according to “the IDD […] shall communicate specific information […] notably the name of any insurance or reinsurance undertaking represented and the relevant insurance classes, if applicable”. Please provide specific examples of the ‘specific information’ a home-State authority/regulatory body may request, and what it may not (if any).

We have a question about two warning controls : BV1438 & BV1453 We are considering in the S.17.01 the “Best estimate claims gross” as the sum of “Future benefit and claims” and “Future expenses and other cash-out flows” In the triangles of S.19.01, we are not considering the “Future expenses and other cash-out flows” Should we must exclude expenses from the amount of the "Best estimate claims gross" of S.17.01 Can you confirm those controls ?

Q&A 2635  clarifies that aggregate limits, can only be considered in scenario-based modules, i.e. the Non-Life Cat module in our context. Is the capital requirement for catastrophe risk based on the maximum possible deterioration of losses under the contracts, which is equal to [Annual Aggregate Limit (AAL)

According to Art. 10 section 2 of the Delegated Regulation, the basic method of asset valuation by insurance companies is valuation at market prices quoted on active markets of the same assets.

1) Can you please confirm that this means that if the OTC markets are more active/liquid than regulated markets (e.g. in case of bonds), the valuation should be taken from the OTC market?

Article 142(6) of Commission Delegated Regulation (EU) 2015/35 defines capital requirement for mass-lapse such as: The capital requirement for mass lapse risk shall be equal to the loss in basic own funds of insurance and reinsurance undertakings that would result from a combination of the following instantaneous events: a) the discontinuance of 70 % of the insurance policies falling within the scope of operations referred to with Article 2(3)(b)(iii) and (iv) of Directive 2009/138/EC, for which discontinuance would result in an increase of technical provisions without the risk margin and where one of the following conditions are met:

Regards new field C0371 (Currency of price). We note this field is not included in the list of fields to not be left blank for OTC derivatives (BV811-1) and the LOG guidance does not give any guidance on applicability. Can EIOPA please confirm if C0371 is always to be completed or the conditions for which it would be expected to be completed and/or not completed.

S.14.04, S.14.05:

ITEM: C0180 Best Estimate Amount of gross best estimate calculated by Product.
Is it possible to report the best estimate in LOB instead of by product?

We have the following two questions regarding QRT S.36.02, Tax 2.8.0: General Comments: We are wondering to which Annex the following passage (ITS_reporting_AnnexII_soloinstructions_S.26.02_to_S.36.05_reviewed 20220615.docx) refers to: S.36.02,

Article 25 states that QRTs S.36.xx are applicable to Solo entities "Insurance and reinsurance undertakings which are not part of a group as referred to in Article 213(2), points (a), (b) or (c), of Directive 2009/138/EC and the parent undertaking of which is a mixed-activity insurance holding company shall submit...". Hence, our understanding is that the negation of this sentence should be used as a reason for not submitting the template for a Solo entity.